Skip to content Skip to footer
Subscribe Now
NEWS

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Shots: Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613 to treat solid tumors with the highest unmet needs Ipsen will secure global rights to SIM0613 outside Greater China, gain manufacturing rights after technology transfer, & assume responsibility for all development activities beyond Greater China, incl. P-I preparation & IND/CTA submissions As…
5 days ago

Read more

Innocare Pharma
NEWS

InnoCare Pharma Reports NMPA’s NDA Acceptance of Zurletrectinib to Treat NTRK Fusion-Positive Solid Tumors

Shots: China’s NMPA has accepted NDA of zurletrectinib (ICP-723) for the treatment of pts (≥12yrs.) with advanced solid tumors having NTRK gene fusions In a registrational trial, zurletrectinib demonstrated favorable safety & strong efficacy, with the ability to overcome acquired resistance to the 1st generation TRK inhibitors in mentioned pts Zurletrectinib is a next-generation pan-TRK inhibitor…
April 17, 2025

Read more

VIEWPOINTS_John Orwin_2023
VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots: John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with Xencor He also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platform The interview gives an understanding of Atreca’s focus on…
June 20, 2023

Read more

Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 2021

Read more